---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-004387"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-05-29T20:05:43+00:00"
generated_at: "2026-05-29T20:08:28.239459+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.15
confidence: "medium"
source: SEC EDGAR
---

# Majority shareholder approves >20% stock issuance at discount; warrant adjustments allowed

## Summary
- CEO Dr. Steve N. Slilaty, holding ~86% voting power, approved issuance of >20% of outstanding shares at discount to Nasdaq min price.
- Consent allows adjustment of Series C Warrants' exercise price or shares in a Share Combination Event.
- Consent allows voluntary adjustment of Series C Warrant exercise prices from time to time.
- Consent effective 20 days after mailing definitive info statement; part of May 19, 2026 public offering.

## SEC filing metadata
- accession: 0001683168-26-004387
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-05-29T20:05:43+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.15
- confidence: medium
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826004387/0001683168-26-004387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826004387/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-004387
- JSON: https://secwatch.observer/filing/0001683168-26-004387.json
- Plain text: https://secwatch.observer/filing/0001683168-26-004387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.